Clinical Trial Search

Primary: Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects. — 15 mg/kg/day

Primary: Number of Participants With Abnormal Physical Examination Findings

Primary: Area Under the Curve From 0 to Infinity (AUC0-inf) of Elbasvir — 1.56; 1.86; 2.28; 2.58 μM•hr

Primary: AUC(0-tz) — 133; 124; 122 μg*h/mL

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 1 participants

Primary: Academic Performance: Grade Point Averages — 85.71; 83.45 per cent — p=0.54

Primary: Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. — 3; 1; 0; 0 Participants

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0 participants

Primary: Cavernosal Artery Mean PSV Before Treatment — 24.5; 28.2 cm/s

Primary: Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of Dosing — 57.1; 87.5; 71.4; 75.0 percentage of participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants

Primary: Safety Profile - Number of Subjects With at Least 1 AE — 1; 2; 3; 4 Participants

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Cephalexin Following a Single Dose — 38.038; 37.913…

Primary: Number of Participants With Solicited Symptoms — 6; 4; 15; 7 participants

Primary: Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m² — 378; 546; 477 ng*hr/mL — p=0.02232